DNLI stock forecast
Our latest prediction for Denali Therapeutics, Inc.'s stock price was made on the Dec. 4, 2019 when the stock price was at 18.16$.
In the short term (2weeks), DNLI's stock price should underperform the market by -5.97%. During that period the price should oscillate between -8.79% and +7.06%.
In the medium term (3months), DNLI's stock price should underperform the market by -9.39%. During that period the price should oscillate between -27.97% and +15.62%.Get email alerts
About Denali Therapeutics, Inc.
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
At the moment the company generates 148M USD in revenues.
On its last earning announcement, the company reported a loss of -0.65$ per share.
The book value per share is 5.17$
Three months stock forecastDec. 4, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|